1. Williams KL. Developing an endotoxin control strategy. Pharm Technol 1998; September:90-102.

2. Cooper JF. Screening active pharmaceutical ingredients and excipients for endotoxin. In: Williams KL, ed. Microbial Contamination Control in Parenteral Manufacturing. New York: Marcel Dekker, 2004:531-540.

3. Nema S, Washkuhn RJ, Brendel RJ. Excipients and their use in injectable products. PDA J Pharm Sci Technol 1997; 51(4):166-171.

4. European Pharmacopoeia. Monograph. 3rd ed, 1997.

5. Croes RV. Maltitol solution, mannitol, sorbitol, sorbitol solution, noncrystallizing sorbitol solution-suggested revisions for harmonization of pharmacopeial specifications and procedures. Pharmacopeial Forum 1998; 24(1).

6. U.S. Dept. of Health and Human Services. FDA Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices. December, 1987.

7. Chowham ZT. The long, difficult, and frustrating process of harmonization of excipient standards. Pharm Technol 1997; March.

8. Stoklosa MJ, Ansel HC. Pharmaceutical Calculations. Philadelphia: Lea & Febiger, 1986.

9. Wade A, Weller PJ, eds. Handbook of Pharmaceutical Excipients. Washington and London: American Pharmaceutical Association and The Pharmaceutical Press, 1994.

10. Cleland JL, Imac A, Boyd B, et al. The stability of recombinant human growth hormone in Poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 1997; 14(4):420 -425.

11. Weary ME. Understanding and setting endotoxin limits. PDA J Pharm Sci Technol 1990; 44(1):16-18.

12. Cooper JF, Br├╝gger P, Fanning M, Matsuura S, Poole S. Alert and action levels for APIs: A collaborative study of pyrogenic gentamicin. Parenteral Drug Association Annual Meeting. New Orleans, December, 2002.

13. Cooper JF, Harbert JC. Endotoxin as a cause of aseptic meningitis after radionuclide cisternography. J Nucl Med 1975; 16:809-813.

14. Twohy C, Duran AP, Munson TE. Endotoxin contamination of parenteral drugs as determined by the LAL method. J Parenter Sci Technol 1984; 30:190-201.

15. Cooper JF, Thoma LA. Screening extemporaneously compounded intraspinal injections with the bacterial endotoxins test. Am J Health Syst Pharm 2002; 59:2426-2433.

16. Powell MT, Nguyen T, Baloian L. Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol 1998; 52:238-311.

Was this article helpful?

0 0

Post a comment